Data management in substance use disorder treatment research: Implications from data harmonization of National Institute on Drug Abuse-funded randomized controlled trials

Ryoko Susukida, PhD¹

Masoumeh Aminesmaeili, MD, MPH^{1, 2}

Ramin Mojtabai, MD, PhD, MPH^{1, 3}

¹Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD, 21205, USA

²Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, No. 486, South Karegar Ave., Tehran, Iran

³Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 N. Wolfe St. Baltimore, MD 21287

Corresponding author:

Ryoko Susukida

624 N. Broadway Room 808, Baltimore, MD, 21205, USA

Telephone: 410-502-9344

Fax: 410-614-7469

Email: rsusuki1@jhu.edu

Running title: Data management in SUD research

Word count: 2,868

Funding: This project was supported by a research award from Arnold Ventures. The content is solely the responsibility of the authors and does not necessarily represent the official views of Arnold Ventures.

Abstract

Background: Secondary analysis of data from completed randomized controlled trials (RCTs) is a critical and efficient way to maximize the potential benefit from past research. De-identified primary data from completed RCTs have been increasingly available in recent years; however, the lack of standardized data products is a major barrier to further use of these valuable data. Pre-statistical harmonization of data structure, variables and codebooks across RCTs would facilitate secondary data analysis including meta-analysis and comparative effectiveness studies. We describe a data harmonization initiative to harmonize de-identified primary data from substance use disorder (SUD) treatment RCTs funded by the National Institute on Drug Abuse (NIDA) available on the NIDA Data Share website.

Methods: Harmonized datasets with standardized data structures, variable names, labels, and definitions and harmonized codebooks were developed for 36 completed RCTs. Common data domains were identified to bundle data files from individual RCTs according to relevant subject areas. Variables within the same instrument were harmonized if at least two RCTs used the same instrument. The structures of the harmonized data were determined based on the feedback from clinical trialists and SUD research experts.

Results: We have created a harmonized database of variables across 36 RCTs with a build-in label, and a brief definition for each variable. Data files from the RCTs have been consistently categorized into eight domains (enrollment, demographics, adherence, adverse events, physical health measures, mental-behavioral-cognitive health measures, self-reported substance use measures, and biologic substance use measures). Harmonized codebooks and instrument/variable concordance tables have also been developed to help identify instruments and variables of interest more easily.

Conclusions: The harmonized data of RCTs of SUD treatments can potentially promote future secondary data analysis of completed RCTs, allowing combining data from multiple RCTs and provide guidance for future RCTs in SUD treatment research.

Keywords: Randomized controlled trials; secondary data analysis; substance abuse treatment; data harmonization

Background

Data sharing of de-identified primary data from randomized controlled trials (RCTs) has been increasingly promoted by the National Institutes of Health (NIH) (1). Secondary analysis of data from the completed RCTs is a critical and efficient way to maximize the potential benefit from past research. Designing RCTs for new treatments should ideally reflect the lessons and implications from the past RCTs. Greater availability of data would also allow investigators not involved in the primary research to confirm the findings of the original investigators, explore relationships of theoretic and clinical interest that were not examined by primary investigators, and conduct more powerful tests of hypotheses through combining multiple datasets. Furthermore, the pooled data would provide cost-effective resources for comparative efficacy studies by allowing comparisons across multiple active treatment arms. These include, for example, analyses of treatment response in under-represented population subgroups and exploration of treatment response heterogeneity in patients with risk profiles. Such data can promote new directions for research by identifying population groups who would most benefit from interventions and hence contribute to ultimately improving clinical practices.

De-identified primary data from completed RCTs have been increasingly available in recent years in various biomedical research fields. There are several organizations making critical efforts to provide researchers with user-friendly and/or harmonized RCT data for further scientific research. Some of the data repositories include the Inter-university Consortium of Political and Social Research (ICPSR), the Yale University of Open Data Access (YODA), the NIMH data archive (2), ClinicalStudyDataRequest.com (CSDR) (3), and Vivli Center for Global Clinical Research Data (4). In the field of substance use disorder (SUD) treatment, the National Institute for Drug Abuse (NIDA) has made data from the completed RCTs publicly available through the NIDA Data Share website (5) to encourage secondary analysis of completed RCTs in substance use disorder (SUD) treatment research. The NIDA Data Share website includes data from completed RCTs which were conducted under 1) the National Drug Abuse Treatment

Clinical Trials Network (CTN), where patients were recruited from a broad range of community-based SUD treatment settings, and 2) the Division of Therapeutics and Medical Consequences (DTMC) program, where patients were recruited through advertisement in various academic institutions, federal therapeutic development institutions, and the pharmaceutical and biotechnology sectors to test effectiveness of innovative SUD pharmacotherapies. Deposited data from NIDA-funded RCTs are an extremely valuable resource for advancing the standard of evidence-based care for SUDs in the United States, where a high prevalence of SUDs is one of the most significant public health issues and there is a critical need for more efficacious interventions for these conditions.

As more data from RCTs have become available, there is also a growing number of secondary analyses of RCT data. However, only a limited number of secondary analyses of RCT data have been conducted and published by entirely independent investigators who were not part of the primary RCT investigative team (6). There have been increasing calls for secondary analyses of RCT data by independent investigators to ensure research reproducibility. The NIDA Data Share website has been providing a valuable resource for secondary analyses of RCT data within the SUD research community.

The NIDA CTN Dissemination Library store all publications that involved analyses of the CTN RCT data. At the time of this writing, there were a total of 636 of published documents including peer-reviewed journals, posters and newsletters, most of which were secondary analyses of data based on NIDA CTN RCTs (7). However, only 34 (5.3%) of these documents were published by entirely independent investigators, perhaps partly due to difficulty to use the RCT data from the NIDA Data Share website. This highlights the importance of maximizing the usability of the data from NIDA-funded RCTs to enable independent investigators to analyze data easily. While the primary data from completed SUD RCTs are currently downloadable from the NIDA Data Share website, the lack of standardized data products with consistent variable

names, labels, and codebooks is a major barrier to further use of these valuable data. Due to these logistical data challenges, this valuable data resource is currently underutilized.

Harmonizing data structure, variables and codebooks across RCTs would facilitate secondary data analysis including meta-analysis and comparative effectiveness studies. The primary purpose of this paper is to describe a data harmonization initiative to harmonize de-identified primary data from NIDA-funded SUD treatment RCTs available on the NIDA Data Share website. We aimed to develop harmonized datasets of 36 NIDA-funded RCTs that were deposited on the NIDA Data share website by September 2018.

Method

NIDA-funded RCTs

There were 36 primary data publicly available from the NIDA Data Share website by September 2018, including one RCT follow-up study (CTN0030A3). We excluded open-label trials, feasibility trials, safety trials, non-randomized trials, and RCTs focusing on non-SUD outcomes from our data harmonization initiative. Table 1 presents the list of 36 RCTs included in this data harmonization initiative. There were 23 RCTs conducted under the CTN, 13 RCTs conducted under the DTMC program. By target substances, 16 RCTs targeted stimulants including cocaine and methamphetamine, 9 RCTs targeted opioids, 8 RCTs targeted any substances, and 3 RCTs targeted nicotine. By intervention types, 23 RCTs tested the effectiveness of pharmacological interventions while 13 RCTs tested the effectiveness of behavioral interventions. The sample size varied from 62 (CTN0052) to 1,285 (CTN0047).

Development of harmonized data format

A number of instruments were utilized in each completed RCT. Instruments included standardized tools in SUD research fields such as the Addiction Severity Index (ASI) and the

Clinical Opiate Withdrawal Scale (COWS). The datasets in the harmonized database were designed so that each data file contains only one instrument and that the number of data files corresponds to the number of instruments used in each RCT. Data files have been named in a consistent manner representing each RCT identifier and instrument name. Each harmonized data file has also been provided in both a comma-separated values (CSV) file and a *Stata* (version 14; Stata Corp, College Station, TX, USA) *.dta data file.

To help users identify the instrument of interest more easily, common data domains were identified to bundle each data file according to its relevant subject area. Furthermore, variables within the same instrument were harmonized if two or more RCTs used the same instrument. The structures of the harmonized data were determined based on the feedback from the advisory board member consisting of clinical trialists and SUD research experts.

Codebooks and supplemental documentations

For some RCTs, NIDA Data Share website provided some data along with codebooks that describe the definitions of each variable (e.g., CTN0037, CTN0044); whereas, for other studies only annotated questionnaires were provided as a guide to using the data (e.g., CTN0001, CTN0004). These data were used for identifying variables, developing uniform variable names and consistent variable and value labels. We also developed standardized codebooks for the harmonized data. The standardized codebooks were produced with the *codebook* command in *Stata*, version 14 (Stata Corp, College Station, TX, USA). Furthermore, we have developed several supplemental documents including 1) a user's guide which documents processing notes for harmonized RCT data, 2) an instrument concordance table, which allows users to identify which instruments are comparable across different RCTs, 3) a variable concordance table, which allows users to identify which variables in each instrument are comparable across different RCTs, and 4) an assessment schedule table which tabulates assessment schedule for main outcome instruments (e.g., ASI) in each study.

Results

Since the inception of this data harmonization initiative in September 2018, we have developed a beta version of the harmonized database of 36 NIDA-funded SUD RCTs and produced standardized codebooks as well as supplemental documentation including a user's guide, concordance tables (for instruments and variables), and assessment schedule table.

Harmonized data structure

Figure 1 presents the data structure of the harmonized data. Each RCT comes with a number of instruments, each of which has been stored in a separate data file. Instruments include not only standardized instruments such as ASI and COWS but also non-standardized instruments such as demographics form that varies in content across studies. The number of instruments ranged from 16 to 48 per RCT. Each instrument is provided in a separate data file and data files are named in a consistent manner. For example, the data file for ASI in CTN0001 is named "CTN0001_ASI." The list of abbreviated names for each instrument (e.g., ASI for Addiction Severity Index) is provided in one of the supplemental documents, the instrument concordance table, which is described below.

All the data files for each RCT have been consistently categorized into eight data domains: 1) *enrollment*, containing information regarding eligibility criteria for RCT participation; 2) *demographics*, containing basic demographic information such as age, sex, and race/ethnicity; 3) *adherence*, containing information regarding the number of visits made and qualitative measures of adherence with treatments; 4) *adverse events*, containing information about medication and therapy related adverse events and often divided into severe and less than severe adverse events; 5) *physical health measures*, containing basic physical health information such as height, weight and blood pressure as well as information on medical history and prior/concomitant medications; 6) *mental-behavioral-cognitive health measures*, containing information regarding psychological well-being based on standardized tools such as Beck

Depression Inventory and 36-Item Short Form Survey; 7) *self-reported substance use measures*, containing information based on self-administered tools such as ASI and Time Line Follow Back Scale; and 8) *biologic substance use measures*, containing information based on objective measures of substance use such as urine toxicology and alcohol breathalyzer.

Data presentation of variables in each data file has been made consistent across different RCTs with a build-in label and brief definition for each variable. The data files were so created that each data file starts with a set of seven variables (Figure 2) that is consistent across all datafiles. These variables allow users to combine multiple datasets from the RCT and also allow them to conduct basic analyses using each datafile separately. The first variable, “studyid”, represents the NIDA study identification code (e.g. CTN0001). The second variable, “usubjid”, represents the de-identified subject identification code. The third variable, “arm”, represents whether a patient was randomly assigned to active treatment or control arms. Names for treatment arms were taken directly from original data files. We created variables “arm1” (treatment arm for phase 1) and “arm2” (treatment arm for phase 2) for study NIDA-CTN0030/0030A, which was a two-step trial. Variable “arm” for those who were not randomized but had baseline assessments was coded either as “not randomized” or left missing. The fourth variable, “assessdays”, represents days since randomization (e.g., -3 = 3 days before randomization) for each assessment. The fourth variable, “visno” represents RCT-specific assessment visit number (e.g., WEEK4V1). The fifth variable, “phase”, represents the phase of the study, which was derived based on “visno” to allow users to distinguish whether assessments were recorded before the active treatment (“BASELINE”), during active treatment (“ACTIVE”), or after active treatment (“FOLLOWUP”). Exceptionally for CTN0030/0030A, which was a two-step trial, we created two values for active phase, “ACTIVE1” (during phase 1 treatment) and “ACTIVE2” (during phase 2 treatment). The seventh variable, “measure”, represents the name of the instruments stored in a data file (e.g., ADDICTION SEVERITY INDEX-LITE). Data files for most of the measures have been structured in a long (longitudinal)

format, where there are multiple assessments recorded vertically across different phases of the study. Because in many cases variables “assessdays”, “visno”, and “phase” were not all available for every assessment due to missing information in original data files, a variable “sequence” (integer starting from one) was created for some instruments, using available variables, which allows users to distinguish multiple assessments.

Codebooks and supplemental documentations

Harmonized codebooks were produced using information from various documents for each CTN study available from the NIDA Data Share Website, including annotated questionnaires, protocols and spreadsheets of data dictionaries. Variable name with its brief description, variable type (string/numeric), the number of missing values, and frequency tabulation have been included for all variables. For string variables (e.g., patient id), the number of unique values has been also presented. For numeric continuous variables (e.g., quantitative measures from a urine sample), mean, standard deviation, and frequency tabulation (percentiles) have been presented. For numeric categorical variables (e.g., qualitative measures from a urine sample), range of values and variable labels for associated numeric values have been presented.

Several supplemental documents were also created. These included first, a *user’s guide*, which briefly describes how the harmonized data files were constructed, and how instruments and variables of interest can be found for secondary data analysis. The *user’s guide* also describes how data files can be merged with each other by providing several examples. Second, we have developed an *instrument concordance table* that helps users to identify which instruments/measures are included in each domain for each RCT. This document is especially useful since instruments/measures under each domain varied for every RCT (Figure 3). The *instrument concordance table* allows users to easily identify comparable instruments/measures across different RCTs. Third, we have created a *variable concordance table* since some items were omitted from instruments/measures in some RCTs (e.g., quantitative measures for urine

toxicology tests were only available for a subset of 36 RCTs). The *variable concordance table* presents the item-level concordance within a particular instrument. Fourth, we have created an *assessment schedule table* showing the timing and frequencies of assessment for major SUD outcome measures such as urine toxicology tests and ASI for each RCT (Figure 4).

Examples of secondary data analyses

Table 2 presents basic descriptive statistics of 36 RCTs. Harmonized data allow researchers to easily pool data multiple RCTs and conduct comparative studies across RCTs. Secondary analyses leveraging the harmonized data have been published by our investigative team, a group of researchers who have not involved in primary data collection of the NIDA-funded RCTs (8-14). First, a series of studies by Susukida et al. (8-12) examined the generalizability of the findings from SUD RCTs to the target populations. These studies used harmonized data of NIDA-funded RCTs described above and compared the characteristics of individuals participating in SUD RCTs with individuals receiving treatment in usual care settings. The main findings of these studies were that individuals recruited into SUD RCTs appear to differ in significant ways from individuals receiving treatment in usual care settings. Specifically, RCT participants had more years of education and a greater likelihood of full-time work compared with people receiving care in usual care settings. In a further step, statistical weighting was used to re-compute the effects from these SUD RCTs such that the RCT participants had characteristics that resembled those of patients in the target populations. Such re-weighting of the samples changed the treatment effects in a number of the RCTs. Most commonly, the positive effects of trials became statistically non-significant after re-weighting the RCT sample to match the target population.

Second, we conducted a study assessing the validity of the psychiatric problems subscale of the ASI (ASI-psych) (13), a detailed measure commonly used in SUD treatment research, to detect psychiatric comorbidity using pooled harmonized data from 11 NIDA-funded RCTs involving 1,660 participants. Our results demonstrated moderate accuracy of the ASI-

psych in detecting the presence of any serious mental disorder against the gold standard of diagnosis based on structured or semi-structured interviews. The results support the utility of ASI-psych in screening psychiatric comorbidity among patients receiving substance use disorder treatments in RCT settings.

Furthermore, in collaboration with biostatistician, we have conducted a study to examine precision and power gains associated with adjustment for baseline variables in stratified RCTs, using the harmonized data of three stratified NIDA RCTs (14). The results demonstrated that the variance of the treatment estimates reduced up to 35% by adjusting for baseline variables, indicating that researchers planning to perform adjustment for strata and additional baseline variables could achieve the same precision with approximately 35% fewer participants.

Conclusions

As the country struggles to tackle the growing problem of SUDs and particularly, the recent opioid epidemic, there is a pressing need for reproducible and generalizable studies to examine various interventions. The NIDA Data Share website includes data from numerous studies involving thousands of patients treated for various SUDs. Secondary analyses of these data can provide useful information by addressing new questions about treatment of SUDs and formulating new hypotheses. Our data harmonization initiative has made these data more accessible and user-friendly to a wide circle of researchers, which would encourage various secondary data analyses and help advance the standard of research and potentially ultimately, treatment, of various SUDs. The societal benefits from the deliverables from this data harmonization initiative are expected to be quite large and timely in the face of critical public health concerns in our nation. Future directions and next steps include the effective dissemination of the harmonized data to encourage secondary data analyses in the broader scientific community.

Acknowledgments

We thank the advisory board members (Dr. Kathleen T. Brady; Dr. Cynthia Campbell; Dr. Walter Ling; Dr. John Rotrosen; Dr. Betty Tai; Dr. Xiaoming Wang; Dr. Li-Tzy Wu) for their valuable feedback on this data harmonization initiative.

Declarations of competing interest

Dr. Susukida and Dr. Aminesmaeili have nothing to disclose. Dr. Mojtabai report grants from the National Institute on Drug Abuse and National Institute of Mental Health during the conduct of the study. Dr. Mojtabai has received research funding and consulting fees from Bristol-Myers Squibb and Lundbeck Pharmaceuticals.

References

1. National Institutes of Health. NIH Data Sharing Policy and Implementation Guidance 2003 [Available from: https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm#goals.
2. NIMH. The National Institute of Mental Health Data Archive (NDA) [02/26/2020]. Available from: <https://nda.nih.gov/about/contact-us.html>.
3. CSDR. Clinical Study Data Request [Available from: <https://www.clinicalstudydatarequest.com/>.
4. Vivli. Center for Global Clinical Research Data [Available from: <https://vivli.org/>.
5. Pan JJ, Nahm M, Wakim P, Cushing C, Poole L, Tai B, et al. A centralized informatics infrastructure for the National Institute on Drug Abuse Clinical Trials Network. Clin Trials. 2009;6(1):67-75.
6. Ebrahim S, Sohani ZN, Montoya L, Agarwal A, Thorlund K, Mills EJ, et al. Reanalyses of randomized clinical trial data. Jama. 2014;312(10):1024-32.
7. The Clinical Trial Network (CTN) dissemination library The University of Washington Alcohol and Drug Abuse Institute The CTN Dissemination Library, [Available from: <http://ctndisseminationlibrary.org/>.
8. Susukida R, Crum RM, Stuart EA, Ebnesajjad C, Mojtabei R. Assessing sample representativeness in randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network. Addiction. 2016;111(7):1226-34.
9. Susukida R, Crum RM, Ebnesajjad C, Stuart EA, Mojtabei R. Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network. Addiction. 2017;112(7):1210-9.
10. Susukida R, Crum RM, Hong H, Stuart EA, Mojtabei R. Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies. Int J Methods Psychiatr Res. 2018;27(4):e1609.
11. Susukida R, Crum RM, Stuart EA, Mojtabei R. Generalizability of the findings from a randomized controlled trial of a web-based substance use disorder intervention. Am J Addict. 2018;27(3):231-7.
12. Ackerman B, Schmid I, Rudolph KE, Seamans MJ, Susukida R, Mojtabei R, et al. Implementing statistical methods for generalizing randomized trial findings to a target population. Addict Behav. 2019;94:124-32.
13. Susukida R, Mojtabei R, Amin-Esmaili M. Validation of Addiction Severity Index (ASI) for Assessment of Psychiatric Comorbidity in National Institute of Drug Abuse Clinical Trials Network. Journal of Dual Diagnosis. 2020;Under-review.
14. Wang B, Susukida R, Mojtabei R, Amin-Esmaili M, Rosenblum M. Model-Robust Inference for Clinical Trials that Improve Precision by Stratified Randomization and Adjustment for Additional Baseline Variables. [Methodology (stat.ME)]. In press 2019.

Figure 1. Structure of harmonized data

Figure 2. Harmonized data presentation of variables in each data file (e.g. CTO0005, Urine Drug Screening data file)

CTO0005 UDS data file														
Study ID "studyid"	Subject ID "usubjid"	Treatment arm "arm"	Days since randomization "assessdays"	Study specific visit ID "visno"	Study phase "phase"	Measures/ instruments "measure"								
studyid	usubjid	arm	assessdays	visno	phase	measure	D1A	D1B	D1C	D2A	D2B	D2C	D3A	
1	CTO0005	05_4891	4.0 mg Ondansetron	-3	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	28	20	.	0	5	.	0
2	CTO0005	05_4891	4.0 mg Ondansetron	28	WEEK4V1	ACTIVE	ADDICTION SEVERITY INDEX LITE	18	20	.	0	1	.	0
3	CTO0005	05_4891	4.0 mg Ondansetron	60	WEEK8V3	ACTIVE	ADDICTION SEVERITY INDEX LITE	12	20	.	0	1	.	0
4	CTO0005	05_8342	4.0 mg Ondansetron	-2	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	20	25	.	0	0	.	0
5	CTO0005	05_8342	4.0 mg Ondansetron	61	WEEK8V3	ACTIVE	ADDICTION SEVERITY INDEX LITE	13	23	.	0	0	.	0
6	CTO0005	05_12200	Placebo	-14	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	10	16	.	10	5	.	0
7	CTO0005	05_12200	Placebo	31	WEEK4V1	ACTIVE	ADDICTION SEVERITY INDEX LITE	6	15	.	3	0	.	0
8	CTO0005	05_36247	Placebo	-10	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	8	8	.	7	6	.	0
9	CTO0005	05_36247	Placebo	37	WEEK4V1	ACTIVE	ADDICTION SEVERITY INDEX LITE	10	6	.	6	4	.	0
10	CTO0005	05_56602	0.25 mg Ondansetron	-12	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	2	10	.	0	10	.	0
11	CTO0005	05_100607	Placebo	-8	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	14	23	.	7	1	.	0
12	CTO0005	05_100607	Placebo	26	WEEK4V1	ACTIVE	ADDICTION SEVERITY INDEX LITE	5	23	.	0	6	.	0
13	CTO0005	05_100607	Placebo	62	WEEK8V3	ACTIVE	ADDICTION SEVERITY INDEX LITE	2	23	.	0	6	.	0
14	CTO0005	05_105642	Not randomized	.	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	4	6	.	0	6	.	0
15	CTO0005	05_107072	0.25 mg Ondansetron	-13	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	10	30	.	0	20	.	0
16	CTO0005	05_107072	0.25 mg Ondansetron	30	WEEK4V1	ACTIVE	ADDICTION SEVERITY INDEX LITE	10	30	.	6	28	.	0
17	CTO0005	05_130936	1.0 mg Ondansetron	-8	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	12	23	.	1	10	.	0
18	CTO0005	05_130936	1.0 mg Ondansetron	25	WEEK4V1	ACTIVE	ADDICTION SEVERITY INDEX LITE	20	25	.	1	10	.	0
19	CTO0005	05_130936	1.0 mg Ondansetron	46	WEEK8V3	ACTIVE	ADDICTION SEVERITY INDEX LITE	15	25	.	1	10	.	0
20	CTO0005	05_133137	0.25 mg Ondansetron	-11	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	0	16	.	0	4	.	1
21	CTO0005	05_133137	0.25 mg Ondansetron	28	WEEK4V1	ACTIVE	ADDICTION SEVERITY INDEX LITE	1	15	.	1	15	.	0
22	CTO0005	05_135020	0.25 mg Ondansetron	-13	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	20	26	.	20	26	.	0
23	CTO0005	05_146359	Not randomized	.	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	3	30	.	0	0	.	0
24	CTO0005	05_151710	0.25 mg Ondansetron	-8	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	0	0	.	0	0	.	0
25	CTO0005	05_151710	0.25 mg Ondansetron	28	WEEK4V1	ACTIVE	ADDICTION SEVERITY INDEX LITE	0	0	.	0	0	.	0
26	CTO0005	05_171483	Not randomized	.	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	20	28	.	15	12	.	0
27	CTO0005	05_176622	1.0 mg Ondansetron	-8	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	14	9	.	14	9	.	0
28	CTO0005	05_176622	1.0 mg Ondansetron	50	WEEK8V3	ACTIVE	ADDICTION SEVERITY INDEX LITE	12	9	.	9	9	.	0
29	CTO0005	05_182325	Placebo	-4	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	6	20	.	6	20	.	0
30	CTO0005	05_189928	0.25 mg Ondansetron	-7	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	6	2	.	2	2	.	0
31	CTO0005	05_192852	4.0 mg Ondansetron	-9	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	8	12	.	0	0	.	0
32	CTO0005	05_192852	4.0 mg Ondansetron	31	WEEK4V1	ACTIVE	ADDICTION SEVERITY INDEX LITE	8	15	.	0	0	.	0
33	CTO0005	05_195100	0.25 mg Ondansetron	-12	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	0	15	.	0	0	.	0
34	CTO0005	05_195100	0.25 mg Ondansetron	38	WEEK8V3	ACTIVE	ADDICTION SEVERITY INDEX LITE	2	0	.	0	0	.	0
35	CTO0005	05_201441	1.0 mg Ondansetron	-11	SCRNBASE	BASLINE	ADDICTION SEVERITY INDEX LITE	15	15	.	0	0	.	0

Figure 3. Excerpt from instrument concordance table

domain	measure	shortname	NIDA-CSF-999	NIDA-CSF-1008	NIDA-CSF-1019	NIDA-CSF-1020	NIDA-CSF-1021	NIDA-CSF-1022	NIDA-CSF-1025	NIDA-CSF-1026	NIDA-CSF-1001	NIDA-CSF-1002	NIDA-CSF-1003	NIDA-CSF-1004	NIDA-CSF-1005	NIDA-CSF-1006	NIDA-CSF-1007	NIDA-CSF-1009	NIDA-CSF-1010	NIDA-CSF-1013	NIDA-CSF-1014	NIDA-CSF-1015	NIDA-CSF-1021	NIDA-CSF-1030	NIDA-CSF-1031	NIDA-CSF-1037	NIDA-CSF-1046	NIDA-CSF-1047	NIDA-CSF-1051	NIDA-CSF-1052	NIDA-CSF-1055	NIDA-CSF-1007	NIDA-CSF-1008	NIDA-CSF-1009
ADHERENCE/COMPLIANCE	CLIENT SATISFACTION QUESTIONNAIRE	CSQ																																
ADHERENCE/COMPLIANCE	COMPLIANCE	COMP																																
ADHERENCE/COMPLIANCE	DOSE ADMINISTRATION RECORD	DOSEA																																
ADHERENCE/COMPLIANCE	FOLLOW-UP ASSESSMENT	FOLLOWUP																																
ADVERSE EVENTS	ADVERSE EVENTS	ADVERSE																																
ADVERSE EVENTS	ADVERSE EVENTS AND CONCOMITANT MEDICATIONS	AECON																																
ADVERSE EVENTS	SERIOUS ADVERSE EVENTS	SAE																																
DEMOGRAPHICS	DEMOGRAPHICS	DEM																																
DRUG USE - BIOLOGIC	ALCOHOL BREATHALYZER	ALB																																
DRUG USE - BIOLOGIC	URINE DRUG SCREEN - AMPHETAMINES	UDS																																
DRUG USE - BIOLOGIC	URINE DRUG SCREEN - COCAINE	UDS																																
DRUG USE - BIOLOGIC	URINE DRUG SCREEN - OPIATES	UDS																																
DRUG USE - BIOLOGIC	URINE DRUG SCREEN - OXYCODONE	UDS																																
DRUG USE - SELF REPORT/SUE	ADDITION SEVERITY INDEX LITE	ASI																																
DRUG USE - SELF REPORT/SUE	ADJECTIVE RATING SCALE FOR WITHDRAWAL	ARS W																																
DRUG USE - SELF REPORT/SUE	ASI LITE DRUG/ALCOHOL USE	SU																																
DRUG USE - SELF REPORT/SUE	SUBSTANCE USE REPORT	SUR																																
DRUG USE - SELF REPORT/SUE	SUBSTANCE USE-CALENDAR ASSESSMENT	CALENDAR																																
ENROLLMENT/RANDOMIZATION/INCLUSION/EXCLUSION CRITERIA		INCEX C																																
HEALTH - GENERAL/PHYSICAL	CHEMISTRIES	CHEM																																
HEALTH - GENERAL/PHYSICAL	CONCOMITANT MEDICATIONS	CONMEDS																																
HEALTH - GENERAL/PHYSICAL	ELECTROCARDIOGRAM	ECG																																
HEALTH - GENERAL/PHYSICAL	HEMATOLOGY	HEMAT																																
HEALTH - GENERAL/PHYSICAL	INFECTIOUS DISEASE ASSESSMENT	INFEC DIS																																
HEALTH - GENERAL/PHYSICAL	MEDICAL HISTORY	MEDHIST																																
HEALTH - MENTAL/BEHAVIOR	BECK DEPRESSION INVENTORY	BECK																																
HEALTH - MENTAL/BEHAVIOR	HAMILTON DEPRESSION RATING SCALE	HAMD																																
HEALTH - MENTAL/BEHAVIOR	HIV RISK BEHAVIOR SCALE	HRBS																																
HEALTH - MENTAL/BEHAVIOR	SID WORKSHEET	SCID																																

Figure 4. Excerpt from Assessment Schedule Table

Cont. Table 2: Study schema of RCTs on stimulant use disorder and the assessment points by instruments

Study ID	Instrument	Study week																														
		-	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	28	36 (9m)	48	52 (12m)	
MDS4	Phase	B	A												F																	
	ASI		√												√																	
	UDS*		3√	3√	3√	3√	3√	3√	3√	3√	3√	3√	3√	3√					√													
	RBM		√												√				√													
CSP1021	Phase	B	A								F																					
	ASI		√				√				√																					
	UDS*		3√	3√	3√	3√	3√	3√	3√	3√	3√		√		√																	
	RBM		√								√																					
CSP1025	Phase	B	A												F																	
	ASI		√				√				√				√					√												
	UDS		3√	3√	3√	3√	3√	3√	3√	3√	3√	3√	3√	3√						√												
	RBM		√											√						√												
CSP1026	Phase	B	A												F																	
	ASI		√						√					√																		
	UDS**		3√	3√	3√	3√	3√	3√	3√	3√	3√	3√	3√	3√					√													
	RBM		√											√																		
CTN31	Phase	B	A								F																					
	ASI		√											√													√					
	UDS		√				√				√			√													√					
	RBM																															

B: Baseline/Screening phase; A: Active treatment phase; F: Follow-up phase; ASI: Addiction Severity Index; UDS: Urine Drug Screening; RBM: Risk Behavior Measures

*Three times a week for benzoylcegonine (BE) and creatinine and once a week for the other drugs

** Three times a week for Methamphetamine and creatinine. Other drugs were examined only at baseline.

Table 1. List of the studies included in the data harmonization initiative

NIDA study code	Study title	N
CSP999	A multicenter clinical trial of buprenorphine in treatment of opiate dependence	736
CSP1008A	A multicenter efficacy/safety trial of buprenorphine/naloxone for the treatment of opiate dependence	326
CSP1019	Double-blind, placebo-controlled trial of selegiline transdermal system for the treatment of cocaine dependence	300
CSP1020	A phase III placebo-controlled, double-blind multi-site trial of lofexidine for opiate withdrawal	68
CSP1021	Double-blind, placebo-controlled multi-center trial of baclofen for the treatment of cocaine dependence	160
CSP1022	Phase 2, double-blind, placebo-controlled trial of selegiline transdermal system (STS) as an aid for smoking cessation	246
CSP1025	Phase 2, double-blind, placebo-controlled trial of topiramate for the treatment of methamphetamine dependence	140
CSP1026	Phase 2, double-blind, placebo-controlled trial of modafinil for methamphetamine dependence	210
CTN0001	Buprenorphine/naloxone versus clonidine for inpatient opiate detoxification	113
CTN0002	Buprenorphine/naloxone versus clonidine for outpatient opiate detoxification	230
CTN0003	Suboxone (buprenorphine/naloxone) taper: a comparison of two schedules	516
CTN0004	Motivational enhancement therapy (met) to improve treatment engagement and outcome in subjects seeking treatment for substance abuse	461
CTN0005	MI (motivational interviewing) to improve treatment engagement and outcome in subjects seeking treatment for substance abuse	423
CTN0006	Motivational incentives for enhanced drug abuse recovery: drug free clinics	454
CTN0007	Motivational incentives for enhanced drug abuse recovery: methadone clinics	403
CTN0009	Smoking cessation treatment with transdermal nicotine replacement therapy in substance abuse rehabilitation program	225
CTN0010	Buprenorphine/naloxone-facilitated rehabilitation for opioid dependent adolescents/young adults	154
CTN0013	Motivational enhancement therapy (MET) to improve treatment utilization and outcome in pregnant substance users	200
CTN0014	Brief strategic family therapy (BSFT) for adolescent drug abusers	482
CTN0015	Women's treatment for trauma and substance use disorders	353
CTN0021	MET to improve treatment engagement and outcome for Spanish-speaking individuals seeking treatment for substance abuse	436
CTN0029	A pilot study of osmotic-release methylphenidate in initiating and maintaining abstinence smokers with ADHD	225
CTN0030	A two-phase randomized controlled clinical trial of buprenorphine/naloxone treatment plus individual drug counseling for opioid analgesic dependence	665
CTN0030A3	Long-term follow-up to ctn-0030 (a two-phase RCTs of buprenorphine/naloxone treatment plus individual drug counseling for opioid analgesic dependence)	375
CTN0031	Stimulant abuser groups to engage in 12-step: evaluation of a combined individual-group intervention to reduce stimulant and other drug use by increasing 12-step involvement	471
CTN0037	Stimulant reduction intervention using dosed exercise (stride)	302
CTN0044	Web-delivery of evidence-based, psychosocial treatment for substance use disorders	507
CTN0046	Smoking-cessation and stimulant treatment (s-cast): evaluation of the impact of concurrent outpatient smoking-cessation and stimulant treatment on stimulant-dependence outcomes	538
CTN0047	Screening, assessment, referral, and treatment in emergency departments (SMART-ED)	1285
CTN0048	Cocaine use reduction with buprenorphine (curb)	302
CTN0051	Extended-release naltrexone vs. Buprenorphine for opioid treatment	570
CTN0052	A randomized controlled evaluation of buspirone for relapse-prevention in adults with cocaine dependence (BRAC)	62
CTO0001	Phase 2, double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence	119
CTO0005	Double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine dependence	65
CTO0007	Phase 2, double-blind, placebo-controlled trial of cabergoline for the treatment of cocaine dependence	140
MDS0004	Phase 2, double-blind, placebo-controlled trial of modafinil for the treatment of cocaine dependence	210
MDS0007	Phase 2, double-blind, placebo-controlled trial of bupropion for methamphetamine dependence	205

Table 2. Socio-demographic characteristics of the harmonized data

Study ID	Arms				Sample size, n	Female, %	Age, mean	White, %	Married, %
	Treatment 1	Treatment 2	Treatment 3	Treatment4/ placebo					
CSP999	Bup(1 mg)	Bup(4 mg)	Bup(8 mg)	Bup(16 mg)	736	32.5	36.0	48.8	26.4
CSP1008A	Bup-Nx	BU	-	Placebo	326	35.0	37.6	60.4	22.2
CSP1019	Selegiline	-	-	Placebo	300	22.0	40.7	26.5	18.7
CSP1020	Lofexidine	-	-	Placebo	68	13.2	41.3	51.5	17.6
CSP1021	Baclofen	-	-	Placebo	160	20.6	42.7	25.6	20.6
CSP1022	Selegiline	-	-	Placebo	246	49.2	46.5	68.7	43.5
CSP1025	Topiramate	-	-	Placebo	140	36.4	38.0	77.9	18.6
CSP1026	Modafinil 200	Modafinil 400	-	Placebo	210	40.9	39.0	73.3	21.9
CTN0001	Bup-Nx	Clonidine	-	-	113	39.8	36.2	55.7	23.0
CTN0002	Bup-Nx	Clonidine	-	-	230	28.3	38.8	40.0	15.7
CTN0003	Bup-Nx(7-d taper)	Bup-Nx(28-d taper)	-	-	516	33.0	35.9	76.5	24.2
CTN0004	MET	-	-	ST	461	29.1	35.3	42.0	15.6
CTN0005	MI	-	-	ST	423	42.1	33.3	71.9	17.0
CTN0006	Incentives	-	-	TAU	454	54.9	35.9	35.7	18.5
CTN0007	Incentives	-	-	TAU	403	43.9	41.9	25.6	10.9
CTN0009	SmC	-	-	TAU	225	48.0	42.1	36.0	18.7
CTN0010	Bup-Nx(12-week)	Bup-Nx(14-day)	-	-	154	41.6	19.7	70.1	5.2
CTN0013	MET	-	-	ST	200	100.0	26.2	37.2	14.5
CTN0014	BFST	-	-	TAU	482	21.4	16.0	40.8	-
CTN0015	SS	WHE	-	-	353	100.0	39.2	48.9	15.9
CTN0021	MET	-	-	CAU	436	10.8	32.7	0.0	29.4
CTN0029	ORMeth	-	-	Placebo	255	43.5	37.8	80.4	-
CTN0030	Bup-Nx+SC	Bup-x+EIC	-	-	665	39.6	33.2	90.8	28.6
CTN0031	STAGE-12	-	-	TAU	471	58.8	38.3	50.3	12.5
CTN0037	Exercise	Health Education	-	-	302	40.1	38.5	45.4	13.2
CTN0044	TES	-	-	TAU	507	37.9	35.4	57.6	14.2
CTN0046	TAU+SmC	-	-	TAU	538	48.0	37.0	59.5	10.8
CTN0047	BS+B	SAR	MS	-	1285	30.1	36.4	38.0	9.5
CTN0051	Nalt-ER	Bup-Nx	-	-	570	33.9	33.9	69.1	9.1
CTN0052	Buspirone	-	-	Placebo	62	37.1	46.1	25.8	12.9
CTO0001	Reserpine	-	-	Placebo	119	29.4	41.0	21.0	17.8
CTO0005	Ondansetron 0.25 mg	Ondansetron 1 mg	Ondansetron 4 mg	Placebo	65	15.4	36.2	38.5	20.0
CTO0007	Cabergoline	-	-	Placebo	140	15.0	40.1	37.9	25.0
MDS0004	Modafinil 200	Modafinil 400	-	Placebo	210	28.1	41.8	39.2	18.6
MDS0007	Bupropion	-	-	Placebo	205	35.1	39.3	68.3	15.6

Abbreviations: Bup: Buprenorphine; Bup-Nx: Buprenorphine-Naloxone; BS+B: Brief Intervention plus Booster; BSFT: Brief Strategic Family Therapy; CAU: Counseling as usual; EIC: Enhanced Individual Counseling; Hisp: Hispanic; HS: High School; MET: Motivational Enhancement Therapy; MI: Motivational Interviewing; MS: Minimal Screening; NA: Not-applicable; Nalt-ER: Naltrexone-ER; NH black: Non-Hispanic black; NH white: Non-Hispanic white; ORMeth: Osmotic-Release Methylphenidate; SAR: Screening, Assessment, and Referral; SC: Standard Counseling; SmC: Smoking cessation; ST: Standard treatment; SS: Seeking Safety; TAU: Treatment as usual TES: Therapeutic Education System; WHE: Women's Health Education